folfoxiri folfoxiri folfoxiri is a chemotherapy regimen for the treatment of advanced colorectal cancer. the role of folfoxiri in colorectal cancer has been reviewed. the chemotherapy regimen is made up of the following four drugs: fol – folinic acid (leucovorin), a vitamin b derivative that modulates/potentiates/reduces the side effects of fluorouracil; f – fluorouracil (5-fu), a pyrimidine analog and antimetabolite which incorporates into the dna molecule and stops dna synthesis; ox – oxaliplatin (eloxatin), a platinum-based antineoplastic agent, which inhibits dna repair and/or dna synthesis; iri – irinotecan (camptosar), a topoisomerase inhibitor, prevents dna from uncoiling and duplicating. it is usually given with bevacizumab, unlike folfirinox for treatment of advanced pancreatic cancer. also, the doses (day 1: irinotecan 165 mg/m2 iv, plus oxaliplatin 85 mg/m2 iv; day 1: leucovorin 400 mg/m2; days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; day 1: bevacizumab 5 mg/kg iv; repeat cycle every 2 weeks) are slightly dissimilar to folfirinox. upfront folfoxiri with bevacizumab can be followed by fluoropyrimidine with bevacizumab maintenance.